CN: 32-1845/R
ISSN: 2095-6975
Cite this paper:
Jiangjiang QIN, Wei WANG, Ruiwen ZHANG. Novel natural product therapeutics targeting both inflammation and cancer[J]. Chinese Journal of Natural Medicines, 2017, 15(6): 401-416

Novel natural product therapeutics targeting both inflammation and cancer

Jiangjiang QIN1, Wei WANG1,2, Ruiwen ZHANG1,2
1 Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA;
2 Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
Inflammation is recently recognized as one of the hallmarks of human cancer. Chronic inflammatory response plays a critical role in cancer development, progression, metastasis, and resistance to chemotherapy. Conversely, the oncogenic aberrations also generate an inflammatory microenvironment, enabling the development and progression of cancer. The molecular mechanisms of action that are responsible for inflammatory cancer and cancer-associated inflammation are not fully understood due to the complex crosstalk between oncogenic and pro-inflammatory genes. However, molecular mediators that regulate both inflammation and cancer, such as NF-kB and STAT have been considered as promising targets for preventing and treating these diseases. Recent works have further demonstrated an important role of oncogenes (e.g., NFAT1, MDM2) and tumor suppressor genes (e.g., p53) in cancer-related inflammation. Natural products that target these molecular mediators have shown anticancer and anti-inflammatory activities in preclinical and clinical studies. Sesquiterpenoids (STs), a class of novel plant-derived secondary metabolites have attracted great interest in recent years because of their diversity in chemical structures and pharmacological activities. At present, we and other investigators have found that dimeric sesquiterpenoids (DSTs) may exert enhanced activity and binding affinity to molecular targets due to the increased number of alkylating centers and improved conformational flexibility and lipophilicity. Here, we focus our discussion on the activities and mechanisms of action of STs and DSTs in treating inflammation and cancer as well as their struc-ture-activity relationships.
Key words:    Cancer    Inflammation    Sesquiterpenoid    MDM2    p53    NF-κB   
Received: 2017-03-18   Revised:
PDF (830 KB) Free
Print this page
Email this article to others
Articles by Jiangjiang QIN
Articles by Wei WANG
Articles by Ruiwen ZHANG

Related Articles:
1. YU Qian, ZENG Ke-Wu, MA Xiao-Li, JIANG Yong, TU Peng-Fei, WANG Xue-Mei.Ginsenoside Rk1 suppresses pro-inflammatory responses in lipopolysaccharide-stimulated RAW264.7 cells by inhibiting the Jak2/Stat3 pathway[J]. Chinese Journal of Natural Medicines, 2017,15(10): 751-757
2. ZHANG Tian-Zhu, YANG Shi-Hai, YAO Jin-Fu, DU Juan, YAN Tian-hua.Sangxingtang inhibits the inflammation of LPS-induced acute lung injury in mice by down-regulating the MAPK/NF-κB pathway[J]. Chinese Journal of Natural Medicines, 2015,13(12): 889-895